


AZD 2066 hydrate

Cat. No.:	HY-110255A		
Molecular Formula:	C ₁₉ H ₁₆ ClN ₅ O ₂ ·1/4H ₂ O		
Molecular Weight:	386.33		
Target:	mGluR		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	AZD 2066 hydrate is a selective, orally active and brain-penetrant antagonist of mGluR5. AZD 2066 hydrate has antinociception effects ^[1] .										
IC₅₀ & Target	mGluR5										
In Vitro	<p>AZD 2066 (1-10 μM) inhibits Ca²⁺ response, with IC₅₀s of 27.2±9.1, 3.56±0.52, 96.2±17.8, and 380±78.0 nM in mGlu5/HEK cells and striatal, hippocampal, and cortical cultures respectively^[2].</p> <p>AZD 2066 (1-10 μM) inhibits the oscillatory Ca²⁺ response which induced by bath application of DHPG, and blocks either DHPG or Quis effects in mGlu5/HEK cells^[2].</p> <p>AZD 2066 (1-10 μM) has less effective in striatal neurons^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>										
In Vivo	<p>AZD 2066 (0.03-30 mg/kg; p.o.) shows discriminative effects in rats^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male Wistar rats (weighing 240-250 g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.03, 0.1, 0.3, 1, 3, 10, 30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o. (60 minutes after administration)</td> </tr> <tr> <td>Result:</td> <td>Caused full and dose-dependent AZD9272-appropriate responding.</td> </tr> </table>			Animal Model:	Male Wistar rats (weighing 240-250 g) ^[1]	Dosage:	0.03, 0.1, 0.3, 1, 3, 10, 30 mg/kg	Administration:	P.o. (60 minutes after administration)	Result:	Caused full and dose-dependent AZD9272-appropriate responding.
Animal Model:	Male Wistar rats (weighing 240-250 g) ^[1]										
Dosage:	0.03, 0.1, 0.3, 1, 3, 10, 30 mg/kg										
Administration:	P.o. (60 minutes after administration)										
Result:	Caused full and dose-dependent AZD9272-appropriate responding.										

CUSTOMER VALIDATION

- ACS Chem Neurosci. 2019 Nov 20;10(11):4558-4570.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Swedberg MDB, et, al. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. J Pharmacol Exp Ther. 2014 Aug; 350(2): 212-22.

[2]. Jong YJI, et, al. Location and Cell-Type-Specific Bias of Metabotropic Glutamate Receptor, mGlu 5, Negative Allosteric Modulators. ACS Chem Neurosci. 2019 Nov 20; 10(11): 4558-4570.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA